Grifols, S.A. (GRFS)

6,36 -0,18 (-2,68%) In data: 12:18PM EDT. Mercato aperto.

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 935 712 200
https://www.grifols.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 23.744

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas H. Glanzmann	Executive Chairman	160,03k	N/D	1958
Mr. Nacho Abia	CEO & Director	N/D	N/D	1968
Mr. Alfredo Arroyo Guerra	CFO & VP	N/D	N/D	1958
Mrs. Eva Bastida Tubau	Corporate Vice President and Director of Scientific & Medical Affairs	N/D	N/D	N/D
Ms. Nuria Pascual Lapeña	VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer	N/D	N/D	1964
Mr. David Ian Bell	Chief Corporate Development, Legal & Data Protection Officer	N/D	N/D	1954
Ms. Maria Teresa-Rioné Llano	Chief Communications Officer	N/D	N/D	1965
Ms. Montserrat Gaja Llamas	Chief Human Resources Officer	N/D	N/D	1965
Mr. Vicente Blanquer Torre	Chief Quality Officer	N/D	N/D	1961
Mr. Alberto Grifols Roura	President of the Bio Supplies Division	N/D	N/D	1959

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Governance aziendale

L'ISS Governance QualityScore di Grifols, S.A. al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 9; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.